These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33387566)

  • 1. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
    Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
    Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
    Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
    J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
    Reynolds VL; Butler P; Abernathy MM; Aschenbrenner L; Best DD; Blank J; Crosby M; Custer L; Escobar PA; Kolaja K; Moggs J; Shuey D; Snyder C; Van Vleet T; Zhou J; Hart TK
    Regul Toxicol Pharmacol; 2020 Nov; 117():104746. PubMed ID: 32911461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey.
    Authier S; Brock WJ; Halpern W; Harris SN; Jones D; McGovern T; McGovern PD; Pugsley MK
    Int J Toxicol; 2021 Dec; 40(6):487-505. PubMed ID: 34569357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development and nonclinical to clinical translational databases: past and current efforts.
    Monticello TM
    Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
    Sistare FD; DeGeorge JJ
    Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Forum Opinion Piece
    Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
    Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can lifecycle management safeguard innovation in the pharmaceutical industry?
    Hering S; Loretz B; Friedli T; Lehr CM; Stieneker F
    Drug Discov Today; 2018 Dec; 23(12):1962-1973. PubMed ID: 30342247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
    Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
    Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
    Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
    Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry perspectives on biomarker qualification.
    Lavezzari G; Womack AW
    Clin Pharmacol Ther; 2016 Feb; 99(2):208-13. PubMed ID: 26378777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership Group.
    Birkebak J; Buckley LA; Dambach D; Musvasva E; Price K; Ralston S; Sacaan A
    Regul Toxicol Pharmacol; 2019 Mar; 102():40-46. PubMed ID: 30576687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The state of the art in secondary pharmacology and its impact on the safety of new medicines.
    Brennan RJ; Jenkinson S; Brown A; Delaunois A; Dumotier B; Pannirselvam M; Rao M; Ribeiro LR; Schmidt F; Sibony A; Timsit Y; Sales VT; Armstrong D; Lagrutta A; Mittlestadt SW; Naven R; Peri R; Roberts S; Vergis JM; Valentin JP
    Nat Rev Drug Discov; 2024 Jul; 23(7):525-545. PubMed ID: 38773351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe survey.
    Collinge M; Neff-LaFord H; Akella S; Fogal B; Fraser K; Jabbour J; Harper K; Maier CC; Malherbe L; Marshall N; Rao GK; Raman K; Skaggs H; Weber F; Fuller CL
    Regul Toxicol Pharmacol; 2024 Jun; 150():105630. PubMed ID: 38642729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.
    Tessier Y; Achanzar W; Mihalcik L; Amuzie C; Andersson P; Parry JD; Moggs J; Whiteley LO
    Nucleic Acid Ther; 2021 Feb; 31(1):7-20. PubMed ID: 33054599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits.
    Mattis C; Bratcher N; Burns M; Carosino C; de Zafra C; Fancher RM; Georgi K; Graff C; Hukkanen RR; Johnson C; Lao Y; Lange A; Lee D; Lepherd M; Maguire S; Malisauskas M; Manuel M; Miranda S; Reed L; Santos R; Sayers B; Shaw D; Shuster D
    Int J Toxicol; 2022 Aug; 41(4):291-296. PubMed ID: 35656559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decade of drug metabolite safety testing: industry and regulatory shared learning.
    Luffer-Atlas D; Atrakchi A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):897-900. PubMed ID: 28797172
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.